Information Provided By:
Fly News Breaks for November 16, 2018
APTO
Nov 16, 2018 | 08:07 EDT
B. Riley FBR analyst Dylan Dupuis started Aptose Biosciences with a Buy rating and $5 price target citing the potential of the company's "two unique first-in-class "drugs entering the clinic to treat different kinds of leukemia. The analyst sees potential for an accelerated path to market for CG-806 to treat acute myelogenous leukemia based on "strong preclinical efficacy and safety data."
News For APTO From the Last 2 Days
There are no results for your query APTO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.